1 Title: Supplementation with short-chain fatty acids and the prebiotic 2FL 2 improves clinical outcome in PD

3

4	Authors: Tobias Hegelmaier, MD ^{1†} , Alexander Duscha, MSc ^{1†} , Christiane Desel, PhD ^{1†} ,
5	Sabrina Fuchs ¹ , Michal Shapira, PhD ^{3,4} , Qihao Shan, MSc ⁵ , Gabriele I Stangl, MD ⁶ , Frank
6	Hirche, PhD ⁶ , Stefan Kempa, PhD ⁷ , András Maifeld, MD, PhD ⁷ , Lisa-Marie Würtele ⁸ , Jana
7	Peplinski ⁸ , Diana Jauk ⁸ , Claudia A. Dumitru, PhD ⁹ , Ute Obermüller-Jevic, PhD ¹⁰ , Svein-Olaf
8	Hustvedt ¹¹ , Nina Timmesfeld, PhD ¹² , Ralf Gold, MD ⁸ , Antonia Zapf, PhD ¹³ , Ibrahim E.
9	Sandalcioglu, MD ⁹ , Sanaz Mostaghim, PhD ⁵ , Horst Przuntek, MD ¹⁴ , Eran Segal, PhD ^{3,4} , Nissan
10	Yissachar, PhD ^{15, ‡,} , Aiden Haghikia, MD ^{1,2, ‡,*}
11	Affiliations:
12	¹ Department of Neurology, Otto-von-Guericke University, Magdeburg, Germany.
13	² German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
14	³ Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
15	⁴ Department of Computer Science and Applied Mathematics, Weizmann Institute of Science,
16	Rehovot, Israel.
17	⁵ Faculty of Computer Science, Otto-von-Guericke University Magdeburg, Magdeburg,
18	Germany.
19	⁶ Institute of Agricultural and Nutritional Sciences, Martin-Luther-University Halle-Wittenberg,

- ²¹ ⁷ Integrative Metabolomics and Proteomics, Berlin Institute of Medical Systems Biology/Max
- 22 Delbrück Center for Molecular Medicine, Berlin, Germany.
- ⁸ Department of Neurology, Ruhr University Bochum, St. Josef Hospital Bochum, Bochum,
- 24 Germany.
- ⁹ Department for Neurosurgery, Otto-von-Guericke University, Magdeburg, Germany.
- ¹⁰ Nutrition & Health Division, GBU Nutrition Ingredients, BASF SE, Ludwigshafen, Germany.
- ²⁷ ¹¹ Nutrition & Health Division, GBU Pharma Solutions, BASF A/S, Oslo, Norway.
- ¹² Department for Medical Informatics, Biometry and Epidemiology, Ruhr-University, Bochum,
- 29 Germany.
- ¹³ Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-
- 31 Eppendorf, Hamburg, Germany.
- ³² ¹⁴ Clinic of Neurology II, EVK Hattingen, Hattingen, Germany.
- ¹⁵ The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan,
- 34 Israel; Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University,
- 35 Ramat-Gan, Israel.
- 36 †equally contributing first authors
- 37 ‡equally contributing authors
- 38 *Corresponding author:
- Aiden Haghikia, Dpt. Neurology, Otto-von-Guericke University, Leipziger Str. 44, 39120
- 40 Magdeburg, Germany, +49-391-6713431, <u>aiden.haghikia@med.ovgu.de</u>

41 **Running Title:**

42 SCFA supplementation in PD.

43 Financial Disclosure/Conflict of Interest:

- 44 Competing interests: U. O.-J. is an employee of BASF SE, Ludwigshafen, Germany. S.-O. H. is
- 45 an employee of BASF A/S, Oslo, Norway. A. H. and R. G. have filed a patent on the supportive
- 46 immunomodulatory effect of C3-C8 aliphatic fatty acids. A. H. and H. P. have filed a patent on
- 47 the prophylactic and/or supportive therapeutic treatment of PD. The other authors declare no
- 48 competing interests.

49 ABSTRACT

50 Background: Parkinson's disease (PD) is associated with dysbiosis, proinflammatory gut 51 microbiome, disruptions to intestinal barrier functions, and immunological imbalance. Microbiota-52 produced short-chain fatty acids promote gut barrier integrity and immune regulation, but their 53 impact on PD pathology remains mostly unknown.

54 Objectives: To evaluate supplementation with short-chain fatty acids as an add-on intervention in55 PD.

Methods: In a randomized double-blind prospective study, 72 PD patients received short-chain
fatty acids and/or the prebiotic fiber 2'-fucosyllactose supplementation over 6 months.

Results: We observed improvement in motor and nonmotor symptoms, in addition to modulation of peripheral immunity and improved mitochondrial respiration in immunocytes. The supplementation had no effect on microbiome diversity or composition. Finally, multiobjective analysis and comprehensive immunophenotyping revealed parameters associated with an optimal response to short-chain fatty acids and/or 2'-fucosyllactose supplementation.

63 Conclusion: Short-chain fatty acids ameliorate clinical symptoms in Parkinson's disease patients
 64 and modulate mitochondrial function and peripheral immunity.

65 **INTRODUCTION**

Parkinson's disease (PD) is one of the most common progressive systemic neurodegenerative 66 disorders, affecting millions of people worldwide. Despite intensive research, the cause of 67 neurodegeneration is not fully understood. The current state of research assumes a multifactorial 68 etiology. In addition to sporadic forms of genetic predisposition, mitochondrial dysfunction, 69 oxidative stress and neuroinflammation, also environmental factors play a crucial role.¹ 70 71 Gastrointestinal symptoms are often the first nonmotor symptoms in PD, in addition to olfactory dysfunction, which in most cases occur years to decades before the first motor symptoms, i.e., 72 rigor, tremor and akinesis.² PD incidence rates are rising in addition to changes in nutrition and 73 the consumption of Western-style diets, which are low in fiber and high in saturated fats and 74 75 refined carbohydrates. These dietary habits lead to a dysbiotic intestinal microbiota and altered metabolome as well as intestinal inflammation.³ Growing evidence supports the idea that microbial 76 dysbiosis, leaky gut syndrome and a proinflammatory intestinal environment are central 77 components of the pathogenesis of PD.⁴⁻⁷ 78

The gut metabolome is essential for metabolic homeostasis but is also involved in communication between the microbiome and the subepithelial structures of the gut, which has multifold systemic implications for the organism. Short-chain fatty acids (SCFAs) are a major group of metabolites involved in the microbiome-gut interaction and are produced through the anaerobic fermentation of dietary fibers. A large proportion of SCFAs are metabolized by colonocytes or in the liver, where they contribute to the energy supply. However, a broad range of intracellular SCFA effects are also mediated by G-protein-coupled receptors and SCFA transporters. These include

86 maintenance of intestinal barrier integrity, mucus production, protection against intestinal and systemic inflammation and blood-brain barrier (BBB) permeability.⁸ In PD patients, the levels of 87 SCFA-producing bacteria and fecal SCFAs are significantly reduced.⁹ In a recent study 88 investigating the potential therapeutic effect of propionate (PA), we observed a putative 89 neuroprotective effect in addition to immune regulation.¹⁰ Targeting the gut-brain axis via the 90 microbiome, metabolome and intestinal barrier is a promising approach for future therapies for 91 PD. Consumption of prebiotic fibers has recently been tested in a small cohort of PD patients over 92 10 days.¹¹ However, SCFA supplementation in PD patients over a prolonged period has not yet 93 been evaluated. 94

95 Here, we conducted a randomized, double-blind prospective study over 6 months to investigate direct supplementation of the SCFAs PA and butyric acid (BA) and the prebiotic 2'-fucosyllactose 96 (2FL).¹² The primary endpoints of this study were the impact on microbiome diversity and 97 98 composition as well as changes of SCFA concentration in stool and serum. Because the study was exploratory, no correction for multiplicity and no confirmatory statements are made. The 99 secondary endpoints were the effect on the clinical parameters defined by The Movement Disorder 100 Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS III), 101 levodopa equivalent daily dose (LEDD), PANDA, and olfactory score. We identified novel 102 mechanistic connections between SCFA supplementation, systemic immunity and clinical 103 outcomes in PD patients. 104

105 METHODS

106 Study design and analysis

The study was performed from November 2019 to August 2020 after being approved by the Ethics
Committee of the Ruhr-University Bochum (November 2019; registration number 19-6713). Prior

109 to participation, all subjects signed informed consent forms. This clinical trial was registered in the German Clinical Trials Register (DRKS; registration number DRKS00027061). A total of 94 110 participants were assessed for eligibility and 72 were confirmed for randomization and assigned 111 to one treatment group upon recruitment. Randomization was performed by permuted block 112 randomization to one of the three study arms. The randomization list was prepared by BASF SE 113 and provided to the hospital pharmacy in a sealed envelope. All patients were instructed to take 114 either 3810 mg PA+BA capsules (BA: 2550 mg; PA: 1260 mg) with 2400 mg placebo, 3250 mg 115 2FL capsules with 3200 mg placebo or 3250 mg 2FL capsules with 3810 mg PA+BA capsules 116 117 daily for up to 6 months in combination with existing PD-specific therapy. The PA+BA, 2FL and placebo were provided as delayed-release capsules by BASF SE. Individual subjects were seen at 118 the outpatient clinic every 3 months after initiation of supplementation and underwent complete 119 neurological assessment performed by a certified Neurostatus C neurologist. Blood and fecal 120 samples were collected at the Department of Neurology, St. Josef Hospital Bochum, at the Clinic 121 of Neurology II, EVK Hattingen, and at the University Clinic of Neurology, UK Magdeburg. 122 Clinical data were evaluated by 2-way ANOVA with time and treatment as factors or mixed effects 123 analysis with patient as random effect. It was not corrected for multiplicity, so the p-values are 124 used as descriptive measures. Fecal samples were immediately frozen at -80°C. Serum tubes were 125 centrifuged at 30 min after the blood draw, and the supernatant frozen at -80°C. For isolation of 126 PBMCs, blood was drawn in EDTA tubes and separated using Cytiva Ficoll-Paque[™] PLUS. 127 128 Isolated cells were frozen in CTL-Cryo medium (Immunospot) and stored at -80°C.

129 Quantification of SCFA levels in serum and fecal samples

130 Methods of sample preparation were previously described.¹⁰ SCFA levels were measured by

131 HPLC–MS/MS (Agilent 1100 HPLC).

132 Metagenomic sequencing and bioinformatics analysis

Metagenomic DNA was extracted using the DNeasy PowerMag Soil DNA extraction kit (Qiagen). 133 Next-generation sequencing (NGS) libraries were prepared using Illumina's Nextera DNA library 134 prep and sequenced on an Illumina NovaSeq sequencing platform with 100 bp single-end reads at 135 a depth of 10 million reads per sample. Reads containing Illumina adapters and low-quality reads 136 were filtered out, and ends of low-quality reads trimmed. Reads were mapped to the human 137 genome using bowtie with inclusive parameters, and matches were discarded. The relative 138 abundance of bacterial species was obtained by an expanded microbial genome reference,¹³ with 139 default parameters. Microbiome α -diversity was calculated by the Shannon diversity index. 140 141 Richness was calculated as the number of species in the sample detected with an abundance of at least 1e-4. All abundances were logarithmically transformed. To evaluate the discriminative power 142 of microbial composition for response prediction, we developed an XGBoost¹⁴ prediction model 143 that exclusively utilizes microbiome features as inputs and outperforms other methods for human 144 microbiome data classification.¹⁵ The receiver operating characteristic (ROC) curves mean and 145 146 standard deviation were calculated using the curves produced in a fivefold cross-validation approach. To ensure the model's robustness, we conducted a label-swapping analysis to determine 147 that the performance of the model was no better than random prediction, resulting in an area under 148 the curve (AUC) value very close to 0.5. To gain insights into the model's interpretability, we 149 utilized SHAP (SHapley Additive explanation)¹⁶ to analyze feature attributes. The SHAP values 150 represent the average change in the model's output when conditioning on a specific feature. 151

152 Immunophenotyping

For in-depth immunophenotyping archived PBMCs were stained according to standard protocols.
Antibodies used and gating strategies applied are listed in Supplementary Tables S1,S2. Staining

panels and gatings were modified based on Monaco et al.¹⁷ Data was recorded on a BD
 FACSCelesta TM with standardized application settings.

157 Treg in vitro assays

Treg suppression assays were performed as previously described¹⁰ using whole blood from a 158 validation cohort of PD patients at baseline and after 14 days of supplementation with 2FL or 159 BA+PA. For Treg/PBMC cocultures with in vitro addition of BA and PA, blood from healthy 160 controls or PD patients without SCFA supplementation was used. Treg/PBMC cells were isolated 161 as described and seeded on a 1:1 ratio in serum free TheraPEAKTM X-VIVOTM 15 (Lonza) without 162 CFSE staining. Cells were stimulated with 5 µg/ml PHA (Phytohemagglutinin, Merck), 150 µM 163 BA (Merck) and 150 µM PA (Merck) for 4 days. Cell culture supernatants were analyzed using a 164 LEGENDplexTM Human Essential Immune Response Panel (BioLegend) and recoded on a BD 165 FACSCelestaTM. 166

167 qPCR analysis of sorted Tregs

PBMCs from the validation cohort were isolated and 5×10^7 cells stained with α CD4-FITC 168 (RPAT4, BD Biosciences), aCD25-APC (BC69, BioLegend) and aCD127-PE (HIL-7R-M21, BD 169 Biosciences). CD4⁺CD25⁺⁺CD127^{lo} Tregs were sorted on a BD FACSAriaTM III. RNA was 170 isolated using an RNeasy Micro kit (Qiagen) and transcribed using a QuantiTect® Reverse 171 Transcription Kit (Qiagen). QPCR was performed on a QuantStudioTM 7 Real-Time PCR system 172 using TaqMan® Fast Advanced Master Mix and TaqMan® Gene Expression assays (Applied 173 Biosystems): B2m: Hs00187842 m1, Ccr8: Hs04969449 m1, Cmc1: Hs00976539 g1, Crot: 174 Hs00221733 m1, Ctla4: Hs00175480 m1, Foxp3: Hs01085834 m1, Il10: Hs00961622 m1, 175 176 *Il17rb*: Hs00218889 m1, *Xpa*: Hs00902270 m1.

177 Seahorse XF Cell Mito Stress Test

Cellular metabolic activity was measured using a Seahorse XFp Cell Mito Stress Test Kit (Agilent Technologies) on a Seahorse XFp analyzer according to the manufacturer's protocol. Frozen PBMCs were thawed and 3x10⁵ cells per well were seeded on poly-D-lysine-coated 6-well Agilent Seahorse XF Cell Culture Microplates in X-VIVOTM 15 (Lonza). Cells were incubated for 24 h at 37°C prior to Seahorse assay performance. Individual parameters were calculated according to the

Seahorse XFp Cell Mito stress test protocol.

184 Multiobjective analysis

Multiobjective analysis (MOA) is based on the concept of multiobjective optimization and is 185 applied to problems with several conflicting objectives, where increasing the quality in one 186 187 objective results in deteriorating the others. Multiobjective problems usually contain a subset of data points that are not dominated by others in the dataset and are located on a front surface if 188 189 mapped to the objective space. The central idea concerns the nondominated sorting of a dataset¹⁸ and then clustering the data according to the so-called fronts. The clinical dataset A of N patients, 190 191 was sorted according to the domination criterion as follows: A data point X dominates a data point Y given the objectives f1 = PANDA, f2 = MDS-UPDRSIII and f3 = olfactory score if: 192

193
$$f_i(X) \leq f_i(X), \forall i \text{ and } \exists j: f_i(X) < f_i(Y)$$

194

183

where \leq and \leq denote better and equal or better, respectively.

By applying the domination criterion to the dataset *A*, a subset of data points that are not dominated by any other was identified. This subset was indicated as Front 1. Next, the same procedure was performed on dataset *A* without the data points in F1. By performing this procedure iteratively, the dataset was sorted into several fronts from F1 (best subset) to Fw (worst subset). For further

analysis we took 20% of patients with the lowest and highest front numbers and sorted them into clusters A_1 and A_2 . For binary correlation-based feature selection the ratio ln(V2/baseline) for every determined physiological parameter was calculated and converted entries into rankings. Rankings were normalized (mean of 0 and standard deviation of 1) and the mean and standard deviation of the parameters was computed within each cluster. In this case, the mean describes the level of deviation of a particular parameter within a cluster from the rest of the population, while the standard deviation describes the level of concentration compared to the rest of the population.

206 Data Sharing:

This study did not generate new unique reagents. All new datasets will be made freely available at the time of publication. Any additional information required to reanalyze the data reported in this work is available from the corresponding author upon request. This paper does not report any original code or algorithms. The code used in this study is freely available at https://www.ci.ovgu.de/Research/Codes.html and on GitHub.

212 **RESULTS**

213 Improved clinical outcome upon 6 months supplementation in PD patients

A total of 72 patients were included and randomly assigned to receive 2FL+placebo, PA+BA+placebo or a combination of 2FL+PA+BA. Study visits with detailed neurological examination and sample collection were performed at the beginning of the study (baseline) and after 3 (Visit1, V1) and 6 months (Visit2, V2) (Supplementary Fig. S1). Study groups were comparable in terms of baseline variables (Supplementary Table S3). Supplementation was generally well tolerated. One patient in the 2FL group discontinued treatment due to a mild nontreatment-associated adverse event, hence no follow up data are available.

We assessed extrapyramidal motor function using the MDS-UPDRS III¹⁹ and LEDD²⁰, olfactory 221 function using the Sniffin' Sticks test²¹ and cognitive function using the PANDA.²² All 3 222 interventions showed a decrease in MDS-UPDRS III scores and LEED over the period of 6 months 223 (Fig. 1A, B). Improvement in olfaction, however, was observed only in the 2FL and combination 224 group 2FL+BA+PA (Fig. 1C), while PANDA revealed an improvement in cognitive functions in 225 all groups (Fig. 1D). In sum, 6 months of supplementation with SCFA and/or 2FL improved motor 226 function, led to a reduction in the LEDD required and positively impacted olfactory and cognitive 227 function in patients with PD. 228

229 Gut microbiome diversity is not altered following supplementation

We collected stool samples from all participants and performed shotgun metagenomic sequencing.
Supplementation did not change microbiome diversity or richness in any of the study groups (Fig.
2A,B) and concentrations of SCFA in fecal or serum samples were not elevated (Supplementary
Fig. S2). Thus, consistent with our previous study¹⁰, SCFA and/or 2FL supplementation did not
result in measurable alterations to gut microbiome composition.

235 SCFA/2FL supplementation modulates immune cell subsets

SCFAs have been shown to exert immunomodulatory effects;^{10, 23} therefore, we performed indepth characterization from cryopreserved peripheral blood mononuclear cells (PBMCs). We detected changes in cell proportions across almost all subsets analyzed (Fig. 2C). Thus, supplementation with 2FL and/or SCFA induces multifaceted alterations in the composition of the peripheral immune compartment.

Since we have previously shown that SCFA improves mitochondrial respiration and restores the suppressive function of regulatory T cells (Treg) in patients with multiple sclerosis $(MS)^{10}$, we

243 recruited a validation cohort with n=4 PD patients receiving either 2FL or BA+PA. Maximal respiration was significantly elevated after 14 days of supplementation (Fig. 2D), suggesting that 244 the intervention positively affected mitochondrial function. We did not detect any changes in Treg 245 suppressive capacity, but sorted Tregs showed an increase in the expression of the mitochondrial 246 genes (Supplementary Fig. S3A-C). We further assessed the functionality of Tregs by coculture 247 248 experiments with and without the addition of BA+PA in vitro. Secretion of pro-inflammatory CXCL10 and IL2 was significantly decreased, while the levels of anti-inflammatory TGFβ and 249 250 IL10 increased (Fig. 2E). In summary, SCFA supplementation improves mitochondrial respiration in immunocytes, inhibits the release of proinflammatory mediators and increases the secretion of 251 anti-inflammatory mediators from immune cells. 252

253 Distinct changes in immune cell subsets in responding patients

While 6 months of supplementation improved motor function, this was not observed in all patients. 254 255 In every intervention group, there were few patients with unchanged or increasing MDS-UPDRS III scores over time (Supplementary Fig. S3D). To gain insight into the mechanisms underlying 256 successful SCFA intervention, we combined all 3 intervention groups and stratified them into 257 responders (R: MDS-UPDRS III V2 < MDS-UPDRS III baseline) and nonresponders (NR: MDS-258 UPDRS III V2 \geq MDS-UPDRS III baseline). We detected significant increases of CD4 T cells 259 after 6 months of intervention (Fig. 3A). Supplementation differentially affected subsets of CD4 260 T cells, with significantly increased Th1- and Th17 cells in the R and NR groups, while the levels 261 of Th2 cells were significantly reduced only in responding patients. The levels of B cells were also 262 significantly reduced both in the R and NR groups (Fig. 3B). Remarkably, the percentages of 263 mucosal-associated invariant T cells (MAIT), nonclassic and intermediate monocyte subsets only 264 significantly changed in responders (Fig. 3B). The percentages of other immune cell subsets were 265

not significantly altered. In summary, supplementation with 2FL and/or SCFA induces a multitude
of changes in the composition of immune cell subsets in the blood regardless of treatment response,
while increased numbers of MAIT cells and decreased numbers of nonclassic and intermediate
monocytes seem to correlate exclusively with intervention-induced clinical improvement.

270 Multiobjective analysis reveals parameters associated with best response to intervention

271 We initially defined responders and nonresponders by a reduction in MDS-UPDRS III after 6 months of supplementation. However, this method did not consider patients showing improvement 272 in olfactory and/or cognitive function or improvement in one score but worsening in another score. 273 Therefore, we devised an MOA to incorporate the various clinical measurements and thus more 274 accurately determine the response to intervention. We performed nondominated sorting on the 275 276 clinical parameter difference (V2 – baseline) with three metrics (objectives) olfactory score, MDS-UPDRS III and PANDA. We selected the 20% of patients who had the lowest and highest front 277 numbers and sorted them into two clusters. These clusters included patients with the best/worst 278 279 response to intervention (Fig. 4A). One major feature in our dataset concerns the different scales and distributions of the parameters, which makes it difficult to use existing statistical testing 280 methodologies²⁴. Therefore, we performed binary correlation-based feature selection to identify 281 282 the physiological parameters that have the strongest correlation with the best/worst response to intervention. Using these two values, we identified the parameters with high levels of deviation 283 that also had low levels of variation within a cluster (Fig. 4B). This approach enabled the 284 285 identification of parameters associated with the best or worst combined clinical response (Fig. 4C). This novel approach of MOA revealed additional immune cell subsets associated with response to 286 intervention. We identified CD4 Tfh cells as the parameter with the highest correlation to clinical 287 response (Fig. 4D). This association was not evident when immune cell data were stratified by 288

median split on MDS-UPDRS III (Fig. 4E). Thus, MOA is a promising novel approach to identify parameters associated with response to intervention in complex datasets with several conflicting metrics describing clinical outcome and a highly diverse repertoire of metrics recorded as potential correlates.

PD patients' microbiome before **2FL+BA+PA** supplementation is associated with response

To assess whether the response to supplementation was affected by the patients' microbiome, we 294 used baseline microbiome abundances, as they may hold a potential to predict the impact of 295 intervention. We devised a prediction model utilizing an XGBoost classifier. The model solely 296 uses baseline microbiome data as its inputs and outputs a prediction of the treatment response. The 297 model based on the microbiome of patients who received only 2FL or BA+PA had no predictive 298 299 capability. However, the model predicted response when it was established based on the baseline microbiome of participants who received 2FL+BA+PA (Fig. 4F). We conducted SHapley Additive 300 301 exPlanations (SHAP) analysis (Fig. 4G) to understand which species had the greatest impact on 302 the model's prediction. Our analysis revealed that Streptococcus sp001556435 and Agathobacter rectalis contributed to the prediction of nonresponders, whereas SFEL01 sp004557245 had a 303 304 significant impact on the prediction of responders. Agathobacter rectalis is a SCFA-producing 305 bacterium. Our study also revealed that the total abundance of SCFA-producing bacteria was significantly different between responders and nonresponders who were treated with 306 2FL+BA+PA; responders had a lower abundance of SCFA-producing bacteria (Fig. 4H). 307

308 **DISCUSSION**

Here, we report that supplementation with SCFA improves clinical outcome in PD patients in a randomized double-blind 6-month prospective study with 72 patients. To our knowledge, this is

the first exploratory study of SCFAs in PD patients showing improvement in motor and nonmotor
functions beyond the level provided by standard medication.

Collectively, improvements in hyposmia, motor and cognitive function as a result of SCFA 313 supplementation show that the intervention has a systemic impact on multiple brain regions. 314 Amelioration of motor and nonmotor symptoms suggests a neuroregenerative element of SCFA 315 supplementation. While we were not able to collect cerebrospinal fluid (CSF) in this study, we 316 have previously shown increased PA concentrations in CSF after supplementation in MS 317 patients.¹⁰ In addition, free fatty acid receptor 3 is expressed on the human brain endothelium, and 318 its interaction protects the BBB from oxidative stress.²⁵ Thus, supplementation with SCFAs may 319 320 also directly impact the BBB and CNS to promote neuroregeneration.

Supplementation did not alter microbial composition. Even though microbial dysbiosis has been 321 reported in PD patients, our results suggest that amelioration of disease symptoms by SCFA and/or 322 2FL supplementation does not require profound changes in gut microbe populations. The SCFA 323 324 concentration in fecal samples also remained unaffected by supplementation, suggesting that excess SCFA is not excreted via stool. Over 95% of SCFAs produced in the colon are absorbed 325 by the gut mucosa in healthy individuals²⁶ or transported via the portal vein to the liver, preventing 326 escape into the systemic circulation.²⁷ Since SCFAs are not passed in the stool and serum levels 327 only marginally increase, SCFAs are most likely swiftly metabolized. 328

Supplementation led to a significant increase in MAIT cells only in responding patients. At barrier surfaces, MAIT cells play an important role in the crosstalk between the host and the microbiome.²⁸ Importantly, a regulatory role for MAIT cells in neuroinflammation through suppression of pathogenic Th1 cells has been shown,²⁹ and reduced numbers of MAIT cells in peripheral blood have been reported in patients with several autoimmune diseases.³⁰ A shift toward

334 proinflammatory states in monocyte populations with a decrease in the levels of classic subsets and an increase in the levels of intermediate subsets with increased HLA-DR expression has been 335 shown in PD,³¹ and a large study on expression quantitative trait loci (eQTL) revealed the 336 overrepresentation of PD-related genes in monocyte populations.³² Decreased absolute counts of 337 Tfh cells have also recently been reported in PD patients,³³ in addition to decreased numbers of 338 circulating anti-inflammatory B-cell subsets, thus implicating defective B-cell regulation as 339 another contributing factor in PD. In summary, we propose that supplementation with SCFAs acts 340 in concert on innate-like lymphoid cells, monocytes and B cells to promote a reduced inflammatory 341 342 immune response in PD patients.

Our prediction model suggests that the patient microbiome can predict the efficacy of 2FL and 343 BA+PA supplementation. Specifically, the composition of the SCFA-producing gut microbiota 344 affected the response, with responders having less SCFA-producing gut microbes, which could 345 help explain why supplementation with SCFA induces a greater response rate among them. If 346 validated in larger studies, such a model can help evaluate the chances of a specific patient 347 benefitting from intervention before it is started. In summary, SCFA supplementation may be a 348 promising disease-modifying strategy in PD, hence, a follow-up phase III clinical trial to 349 investigate the therapeutic potential of SCFAs in PD is warranted. 350

351 Acknowledgment:

We thank Cathrine Husberg from BASF for her scientific contribution and energetic support. We thank Bärbel Henke from the Clinic of Neurology II, Hattingen for archiving the biomaterials. We thank Grazyna Debska-Vielhaber from the Department of Neurology, Magdeburg, for performing the seahorse assay. The help of Roland Hartig from the multiparametric bioimaging and cytometry

- 356 platform (MPBIC) of the Otto-von-Guericke University Magdeburg with FACSAria cell sorting
- 357 is greatly acknowledged.

358 Author's Roles:

- 359 Conceptualization: TH, AD, CD, UOJ, RG, HP, NY, AH
- 360 Methodology: TH, AD, CD, GIS, FH, SK, AM, NY, AH
- 361 Software: MS, QS, SM, ES, NY
- 362 Formal Analysis: TH, AD, CD, SF, MS, QS, GIS, FH, SK, AM, CAD, NT, AZ, IES, SM, ES,
- 363 NY, AH
- 364 Investigation: TH, AD, CD, SF, MS, FH, AM, LMW, JP, DJ, CAD
- 365 Resources: UOJ, SOH
- 366 Data Curation: TH, AD, CD, SF, MS, QS, LMW, JP, DJ, SM, ES, NY, AH
- 367 Writing Original Draft: TH, AD, CD, NY, AH
- 368 Writing Review & Editing: TH, AD, CD, MS, GIS, AZ, IES, SM, HP, ES, NY, AH
- 369 Visualization: TH, AD, CD, SF, MS, QS, NY, AH
- 370 Supervision: RG, HP, ES, NY, AH
- 371 Project Administration: TH, AD, CD, HP, AH
- 372 Funding Acquisition: UOJ, SOH, HP, AH

373 **REFERENCES**

- 1. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers 2017;3:17013.
- 2. Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev
- 376 Neurosci 2017;18(8):509.
- 377 3. Zinocker MK, Lindseth IA. The Western Diet-Microbiome-Host Interaction and Its Role in
- 378 Metabolic Disease. Nutrients 2018;10(3).

- 4. Cryan JF, O'Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological
- 380 disorders. Lancet Neurol 2020;19(2):179-194.
- 5. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with
- 382 sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's
- 383 disease. PLoS One 2011;6(12):e28032.
- 6. Nie S, Wang J, Deng Y, Ye Z, Ge Y. Inflammatory microbes and genes as potential biomarkers
 of Parkinson's disease. NPJ Biofilms Microbiomes 2022;8(1):101.
- 386 7. Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the
- 387 Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ
- 388 Parkinsons Dis 2021;7(1):27.
- 8. Visconti A, Le Roy CI, Rosa F, et al. Interplay between the human gut microbiome and host
 metabolism. Nat Commun 2019;10(1):4505.
- 9. Unger MM, Spiegel J, Dillmann KU, et al. Short chain fatty acids and gut microbiota differ
 between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat Disord
 2016;32:66-72.
- 10. Duscha A, Gisevius B, Hirschberg S, et al. Propionic Acid Shapes the Multiple Sclerosis
 Disease Course by an Immunomodulatory Mechanism. Cell 2020;180(6):1067-1080 e1016.
- Hall DA, Voigt RM, Cantu-Jungles TM, et al. An open label, non-randomized study
 assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants. Nat
 Commun 2023;14(1):926.
- Suligoj T, Vigsnaes LK, Abbeele PVD, et al. Effects of Human Milk Oligosaccharides on
 the Adult Gut Microbiota and Barrier Function. Nutrients 2020;12(9).

- Leviatan S, Shoer S, Rothschild D, Gorodetski M, Segal E. An expanded reference map of
 the human gut microbiome reveals hundreds of previously unknown species. Nat Commun
 2022;13(1):3863.
- 404 14. Chen T, Guestrin C. XGBoost: A Scalable Tree Boosting System. Proceedings of the 22nd
- 405 ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. San
- 406 Francisco, California, USA: Association for Computing Machinery; 2016. p. 785–794.
- 407 15. Wang XW, Liu YY. Comparative study of classifiers for human microbiome data. Med
 408 Microecol 2020;4.
- 409 16. Lundberg SM, Erion GG, Lee S-I. Consistent Individualized Feature Attribution for Tree
- 410 Ensembles. ArXiv 2018;abs/1802.03888.
- 411 17. Monaco G, Lee B, Xu W, et al. RNA-Seq Signatures Normalized by mRNA Abundance
- Allow Absolute Deconvolution of Human Immune Cell Types. Cell Rep 2019;26(6):1627-1640
 e1627.
- 18. Deb K, Agrawal S, Pratap A, Meyarivan T. A Fast Elitist Non-dominated Sorting Genetic
 Algorithm for Multi-objective Optimization: NSGA-II. 2000; Berlin, Heidelberg: Springer Berlin
 Heidelberg. p. 849-858.
- 417 19. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision
 418 of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and
 419 clinimetric testing results. Mov Disord 2008;23(15):2129-2170.
- 420 20. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa
- 421 dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25(15):2649-2653.
- 422 21. Cavaco S, Goncalves A, Mendes A, et al. Abnormal Olfaction in Parkinson's Disease Is
- 423 Related to Faster Disease Progression. Behav Neurol 2015;2015:976589.

- 424 22. Michels J, van der Wurp H, Kalbe E, et al. Long-Term Cognitive Decline Related to the
- 425 Motor Phenotype in Parkinson's Disease. J Parkinsons Dis 2022;12(3):905-916.
- 426 23. Correa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA. Regulation of immune cell
- 427 function by short-chain fatty acids. Clin Transl Immunology 2016;5(4):e73.
- 428 24. Lualdi M, Fasano M. Statistical analysis of proteomics data: A review on feature selection.
- 429 J Proteomics 2019;198:18-26.
- 430 25. Hoyles L, Snelling T, Umlai UK, et al. Microbiome-host systems interactions: protective
 431 effects of propionate upon the blood-brain barrier. Microbiome 2018;6(1):55.
- 432 26. Salminen S, Bouley C, Boutron-Ruault MC, et al. Functional food science and
 433 gastrointestinal physiology and function. Br J Nutr 1998;80 Suppl 1:S147-171.
- 434 27. Bloemen JG, Venema K, van de Poll MC, Olde Damink SW, Buurman WA, Dejong CH.
- Short chain fatty acids exchange across the gut and liver in humans measured at surgery. Clin Nutr
 2009;28(6):657-661.
- 437 28. Amini A, Pang D, Hackstein CP, Klenerman P. MAIT Cells in Barrier Tissues: Lessons from
 438 Immediate Neighbors. Front Immunol 2020;11:584521.
- 439 29. Miyazaki Y, Miyake S, Chiba A, Lantz O, Yamamura T. Mucosal-associated invariant T
 440 cells regulate Th1 response in multiple sclerosis. Int Immunol 2011;23(9):529-535.
- 30. Mechelli R, Romano S, Romano C, et al. MAIT Cells and Microbiota in Multiple Sclerosis
 and Other Autoimmune Diseases. Microorganisms 2021;9(6).
- 31. Thome AD, Atassi F, Wang J, et al. Ex vivo expansion of dysfunctional regulatory T
 lymphocytes restores suppressive function in Parkinson's disease. NPJ Parkinsons Dis
 2021;7(1):41.

451	Tables and Figure Legends
450	
449	Parkinson Disease: A Cross-sectional Study. Neurol Neuroimmunol Neuroinflamm 2022;9(2).
448	33. Li R, Tropea TF, Baratta LR, et al. Abnormal B-Cell and Tfh-Cell Profiles in Patients With
447	neurodegenerative risk alleles in leukocytes. Science 2014;344(6183):519-523.
446	32. Raj T, Rothamel K, Mostafavi S, et al. Polarization of the effects of autoimmune and

Fig. 1. Improved clinical outcome upon supplementation. Clinical parameters determined at the first study visit (Baseline) and at the three (V1) and six (V2) month follow-ups. (A) MDS-UPDRS III, (B) LEDD, (C) olfactory score and (D) PANDA. Data plotted as before-after for each patient (gray) and mean (black) \pm SEM. Tested by 2-way ANOVA (C, D) or mixed effects analysis (E, F). **** p<0.0001, *** p< 0.001, ** p< 0.01, *p < 0.05.

Fig. 2. Effect of supplementation on the gut microbiome and immune cells. Shotgun 457 metagenomic sequencing of n=71 stool samples. (A) Shannon diversity, (B) richness of gut 458 microbiota at baseline and V2. (C) Ratio of immune subsets at baseline (red) and 6 months (V2, 459 blue). Mean (solid line) ± SD (dashed lines), all interventions pooled. (D) Mitochondrial 460 respiration; validation cohort at baseline (V0) and after 14 days of (V1, n=3 2FL or BA+PA). Left: 461 Oxygen-consumption rate (OCR) over time, middle: Maximal and right: Basal respiration, mean 462 \pm SD, significance determined by T test. (E) Treg/PBMC coculture assay of n=5 healthy controls 463 (HC) or PD patients, in vitro addition of BA+PA. Data presented as mean ± SD, significance 464 determined by Friedman multiple comparisons test. 465

466 Fig. 3. Supplementation differentially affects immune cell subsets in responding patients. (A)

467 Proportions of CD4-, Th1-, Th17- and Th2 T cells among PBMCs, depicted as median split MDS-

UPDRS III responder/nonresponder, matched baseline and V2, mean \pm SEM. Significance was 468 determined by paired T test. (B) Proportions of B cells, MAIT, nonclassic and intermediate 469 in PBMCs depicted as median split MDS-UPDRS III 470 monocyte populations responder/nonresponder, matched baseline and V2, mean \pm SEM. Significance was determined by 471 paired T test. *** p < 0.001, ** p < 0.01, *p < 0.05. 472

Fig. 4. Multiobjective analysis and prediction modeling reveal parameters associated with 473 the best/worst response to intervention. (A) Nondominated sorting based on olfactory score, 474 MDS-UPDRS III and PANDA (V2 - baseline). The clusters of patients with the best (red) and 475 worst (blue) 20% performances. (B) Examples of an uncorrelated (upper panel) and a correlated 476 477 parameter (lower panel). Solid points depict ranking (not to scale), and transparent points the raw values, data points in the best cluster (red). Mean of all rankings (solid black line) and mean only 478 in the best cluster (dashed red line). (C) Nondominated ranking of physiological parameters 479 associated with the best/worst response. (D) Proportions of CD4 Tfh cells from patients within the 480 best and worst clusters, matched baseline and V2, black line mean \pm SEM. (E) Proportions of CD4 481 Tfh cells in all patients, median split MDS-UPDRS III responder/nonresponder, matched baseline 482 and V2, black line mean ± SEM. Significance was determined by paired T test. (F) Prediction 483 model for distinguishing R from NR: ROC curve of a prediction model based solely on 484 485 microbiome baseline features (blue). (G) SHAP analysis of the model. (H) Abundances of SCFAproducing bacteria before supplementation with 2FL+BA+PA, *p < 0.05. 486 Supplementary Fig. S1. CONSORT 2010 flow diagram. CONsolidated Standards of Reporting 487

487 Supplementary Fig. S1. CONSORT 2010 now diagram. COnsondated Standards of Reporting
 488 Trials: Schematic representation of the randomized double-blind prospective study.

489 Supplementary Fig. S2. SCFA concentration in stool and serum is not altered after

490 supplementation. Concentrations of PA and BA in stool (A) and in serum (B) samples measured

- 491 by HPLC-MS/MS. Data are plotted as before-after for each patient (gray) and mean (black) +/-
- 492 SEM. Tested by 2-way ANOVA with Sidak's multiple comparisons test.

493 Supplementary Fig. S3: Supplementation with SCFA does not boost the suppressive capacity

- 494 of Tregs but increases the expression of mitochondrial genes. (A) Treg/PBMC suppression
- 495 assay at baseline (V0) and 14-day follow-up (V1), samples from validation cohort; MACS-sorted
- 496 cells. (**B**, **C**) Gene expression in sorted Tregs from validation cohort; FACS-sorted cells. (**B**)
- 497 Heatmap of fold changes follow-up (V1) and (C) individual $2^{-\Delta}CT$ values for Crot and Xpa.
- 498 Housekeeping B2m, time points compared by Wilcoxon matched pairs test. (D) Responders (R:
- 499 MDS-UPDRS III V2 < MDS-UPDRS III baseline) and nonresponders (NR: MDS-UPDRS III V2
- \geq MDS-UPDRS III baseline) stratified by group. Data plotted as heatmap (ratio V2/baseline) and
- 501 MDS-UPDRS III before-after for each patient; responders (blue) and nonresponders (pink).
- 502 Supplementary Table S1: List of antibodies used for in-depth immunophenotyping.
- Supplementary Table S2: Gating strategies for in-depth immuno-phenotyping of immune cell
 subsets. Adapted from Monaco et al.¹⁷.
- Supplementary Table S3. Demographic data and characteristics of patients prior to therapeutic intervention. Main demographics and clinical and treatment characteristics of participants at study entry. Data are presented as the mean \pm SD or n (%).

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.













Supplementary Figure S1

CONSORT 2010 Flow Diagram



Supplementary Figure S2





Supplementary Figure S3

Surface	Clone	Fluorochrome	Company	Cat-Nr.	Panel
Marker					
CD3	UCHT1	FITC	BioLegend	300440	1, 2, 4
CD4	RPAT4	APC Fire 750	BioLegend	300560	1
CD25	M-A251	BV785	BioLegend	356140	1
CD127	A019D5	APC	BioLegend	351316	1
CXCR5	J25204	PE/Dazzle 594	BioLegend	356928	1
CD45RA	H100	BV605	BioLegend	304134	1,2
CCR7	G043H7	PerCP/Cy5.5	BioLegend	353220	1,2
CCR6	11A9	PE	BD	559562	1
CXCR3	G025H7	BV650	BioLegend	353730	1
CCR4	L2A1H4	BV421	BioLegend	359414	1
CD8	SK1	APC Fire 750	BioLegend	344746	2
CD161	HP3G10	PE	BioLegend	339904	2
Vα7.2	3C10	BV785	BioLegend	351722	2
ΤCR γ/δ	11F2	APC	Miltenyi	130-113-500	2
Vα2	B6	BV421	BioLegend	331428	2
CD19	H1B19	FITC	BioLegend	302206	3, 4
IgD	1A6-2	PE/Dazzle 594	BioLegend	348240	3
CD45	H130	Alexa Fluor 700	BioLegend	304024	3, 4
CD27	323	BV421	BioLegend	302824	3
CD38	HIT2	APC	BioLegend	303510	3
CD34	563	PE	BD	550761	3
CD11c	B-LY6	APC	BD	559877	4
CD14	HCD14	PE/Dazzle 594	BioLegend	325634	4
CD16	3G8	APC Fire 750	BioLegend	302060	4
CD56	HCD56	PerCP/Cy5.5	BioLegend	318322	4
CD11b	ICRF44	PE	BioLegend	301306	4
CD123	6H6	BV605	BioLegend	306026	4
HLA-DR	L243	BV785	BioLegend	307642	4

Supplementary table S1: List of antibodies used for in-depth immunophenotyping.

Panel 1 - CD4 T cells				
Cell type	ell type Gating strategy			
CD4+ T cells T follicular helper (Tfh) T regulatory cells (Tregs) T helper 1 (Th1) T helper 1/T helper 17 (Th1/17) T helper 17 (Th17) T helper 2 (Th2) T CD4 terminal effector (TE) T CD4 Naïve	CD3 ⁺ CD4 ⁺	CXCR5 ⁺ CXCR5 ⁻ CD25 ^{high} C CXCR5 ⁻ CD127 ⁺ C CCR7 ⁻ CD45RA ^{low} CXCR5 ⁻ CD127 ⁺ C CCR7 ⁺ CD45RA ^{high}	CD127 ^{low} D25 ^{-/low} CXCR3 ⁺ CCR6 ⁻ D25 ^{-/low} CXCR3 ⁺ CCR6 ⁺ D25 ^{-/low} CXCR3 ⁻ CCR6 ⁺ D25 ^{-/low} CXCR3 ⁻ CCR6 ⁻ CCR4 ⁺ D25 ^{-/low} CXCR3 ⁻ CCR6 ⁻ CCR4 ⁻ CR25 ^{-/low} CXCR3 ⁻ CCR6 ⁻ CCR4 ⁻	
Panel 2 - CD8, γ/δ and MAIT T	cells			
Cell type Gating strategy				
CD8+ T cells		TCR γ/δ^{-}	$CD16^{high} NOT V\alpha7.2^+$	
$\gamma/\delta Vd2^+$ (T $\gamma\delta Vd2^+$) $\gamma/\delta Vd2^-$ (T $\gamma\delta$ non-Vd2+)		TCR γ/δ^+	Vd2 ⁺ Vd2 ⁻	
MAIT	CD3+	TCR γ/δ^- Vd2 ⁻	$V\alpha7.2^+$ CD161 ^{high}	
T CD8 Naïve	CDS	· · · ·	CCR7 ⁺ CD45RA ⁺	
T CD8 central memory (CM)		$CD8^+ TCR \gamma/\delta^-$	CCR7 ⁺ CD45RA ⁻	
T CD8 effector memory (EM)		Vd2	CCR7 ⁻ CD45RA ⁻	
T CD8 terminal effector (TE)			$CCR7^{-}CD45RA^{+}$	
PANEL 3 - B cells and Progenit	tors			
Cell type	Gating	strategy		
Progenitors		$CD34^+ CD45^{low}$		
Total B cells (B cells) Naïve B cells (B naïve) Nonswitched memory B cells	CD45 ⁺		$CD27^{-} IgD^{+}$ $CD27^{+} IgD^{+}$	
(DINSIN) Exhausted B cells (BEX)	CD45	CD19 ⁺ CD34 ⁻	CD27 ⁻ IgD ⁻	
Switched memory B cells			$CD27^{+}$ IgD $CD38^{low}$	
(BSM)				
Plasmablasts			CD27 ⁺ IgD ⁻ CD38 ^{high}	
Panel 4 - Monocytes, DCs, NK	rells. Lov	v-density hasonhils		
Cell type	Gating	strategy		
NK cells			CD16 ^{+/-} CD56 ^{+/low} CD14 ⁻	
			CD11c	
Classic (C) monocytes			CD14 ⁺ CD16 ⁻	
Intermediate (I) monocytes		CD11c ⁺	CD14 ⁺ CD16 ⁺	
Nonclassic (NC) monocytes	CD45'		$CD14^{low} CD16^+$	
Myeloid dendritic cells (mDCs)	CD3		HLA-DR ⁺ CD11c ⁺ CD123 ^{low}	
Plasmacytoid dendritic cells			HLA-DR ⁺ CD11c ⁻ CD123 ⁺	
(pDCs)		CD16 CD56		
Low-density (LD) basophils			HLA-DR ⁻ CD123 ⁺ CD11b ⁺	

Supplementary table S2: Gating strategies for in-depth immuno-phenotyping of immune cell subsets. Adapted from Monaco et al. (17).

Characteristics	PA+BA+placeb	o 2FL+placebo	2FL+PA+BA
	(n=24)	(n=24)	(n=24)
Female sex	13 (54.2%)	9 (37.5%)	13 (54.2%)
Age, years	62(±9)	67 (±12)	65 (±8)
Duration of disease, years	7 (±7)	6 (±6)	4 (±4)
BMI	26 (±4)	26 (±3)	25 (±3)
Subgroups			
akinetic-rigid	8 (33.3%)	9 (37.5%)	11 (45.8%)
equivalent	14 (58.3%)	12 (50%)	12 (50%)
tremordominant	2 (8.3 %)	3 (12.5%)	1 (4.17%)
Medication	, ,		``´´
LEDD [mg]	770 (±302)	785 (±267)	756 (±261)
95% CI	642.1-897.1	672.2-897.3	646-866.5
Benserazide	24 (100%)	22 (91.7%)	23 (95.8%)
Carbidopa	4 (16.7%)	5 (20.8%)	2 (8.3%)
Piribedil	2 (8.3%)	0	2 (8.3%)
Rotigotine	2 (8.3%)	3 (12.5%)	3 (12.5%)
Ropinirole	2 (8.3%)	1 (4.17%)	2 (8.3%)
Pramipexole	4 (16.7%)	2 (8.3%)	4 (16.7%)
Rasagiline	13 (54.2%)	8 (33.3%)	14 (58.3%)
Selegiline	3 (12.5%)	9 (37.5%)	3 (12.5%)
Safinamide	2 (8.3%)	1 (4.2%)	2 (8.3%)
COMT-inhibitor	6 (25%)	8 (33.3%)	9 (37.5%)
Amantadine	2 (8.3 %)	2 (8.3 %)	1 (4.2%)
Apomorphine	0	0	0
Anticholinergics	0	1 (4.2%)	0
Clozapine	1 (4.2%)	0	2 (8.3%)
Quetiapine	1 (4.2%)	3 (12.5%)	1 (4.2%)
MDS-Unified Parkinson's Disease	, , , , , , , , , , , , , , , , , , ,		()
Rating Scale			
MDS-UPDRS I	10 (±10)	17 (±12)	17 (±13)
95% CI	12.6-21	12.1-22.5	11.2-22.1
MDS-UPDRS II	9 (±6)	9 (±8)	10 (±9)
95% CI	6.8-12.1	6.3-12.7	6-13.4
MDS-UPDRS III	29 (±17)	33 (±16)	30 (±16)
95% CI	22.1-36.3	26.3-40	23-36.8
MDS-UPDRS IV	3 (± 3)	5 (±5)	3 (±3)
95% CI	1.8-4.2	2.5-6.3	1.4-4.1
Hoehn & Yahr scale	2 (±1)	2 (±1)	2 (±1)
95% CI	1.9-2.5	1.9-2.4	1.9-2.7
PANDA	25 (±4)	33 (±16)	30 (±16)
95% CI	23.7-26.7	18.9-24.8	20.8-26.1
Olfactory score	8 (±3)	7 (±3)	7 (±3)
95% CI	6.8-9	5.9-8.1	5.6-8.1

Supplementary table S3: Demographic data.